PLx Pharma Inc.
PLXP · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.04 | -0.13 |
| FCF Yield | -59.07% | -26.89% | -15.18% | -6.06% |
| EV / EBITDA | 0.56 | -1.84 | -2.30 | 41.78 |
| Quality | ||||
| ROIC | -29.17% | -31.72% | -11.95% | -32.20% |
| Gross Margin | -278.24% | -69.77% | 43.88% | 43.95% |
| Cash Conversion Ratio | 1.29 | 1.53 | 1.57 | -3.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 337.34% | 383.32% | 245.08% | 143.94% |
| Free Cash Flow Growth | 39.32% | -7.14% | -26.43% | -48.50% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 2.08 | 2.05 | -19.18 |
| Interest Coverage | -91.08 | -501.31 | -6,065.33 | -405.18 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.21 | 0.30 | 0.36 |
| Cash Conversion Cycle | -84.16 | -383.83 | -653.27 | -785.42 |